We examined the bone changes in recombinant human granulocyte colony-stimulating factor (rhG-CSF)-treated young and young adult rats in order to investigate the effect of age-related conditions of bone growth on the bone changes induced by rhG-CSF. Recombinant human G-CSF (100 and 1,000 &mu;g/kg/day) was given to rats by daily intravenous injection for 28 days starting at the age of either 6 or 14 wk, and the hindlimb bones were evaluated histopathologically. In the young rats, bone lesions were observed in the 100-and 1,000-&mu;g/kg groups. In the young adult rats, lesions were found only in the 1,000-&mu;g/kg group. The lesions involved accelerated osteoclastic bone resorption and osteogenesis due to intramembranous ossification, and there was no age-related difference in these histopathological findings. However, both the incidence of bone involvement and the severity of lesions were greater in the young rats than in the dose-matched young adult rats. The results suggest that the higher dose of rhG-CSF may intrinsically induce bone lesions of a particular histopathological nature in rats regardless of their age, and the action of rhG-CSF on bone may be stronger in young growing rats than in young adults.
INTRODUCTION
A large number of studies have suggested that colonystimulating factors (CSFs) regulate the proliferation and differentiation of hematopoietic progenitor cells (4) and that granulocyte CSF (G-CSF) acts on the granulocyte lineage and enhances some functions of mature granulocytes (4) . It has been established that osteoclasts, the principal cells responsible for bone resorption, are derived from hematopoietic stem cells (20) and that the CSFs, especially macrophage CSF, regulate the proliferation and differentiation of osteoclast progenitors (2, 6, 8, 11, 13, 14, 17, 19, 22, 24) . Keller and Smalling (7) and Suzuki et al (21) have recently demonstrated that bone changes characterized by accelerated osteoclastic bone resorption and osteogenesis are observed in growing rats exogenously administered high doses of recombinant human G-CSF (rhG-CSF) for a long period. We observed that those changes are frequently found at the site of physiologically active bone resorption in the growth phase, that is, the trabeculae of metaphyseal spongy bone and the endosteum region of diaphyseal compact bone (21) . This finding suggests that the development of bone changes induced by rhG-CSF may be related to age-dependent bone conditions including the bone growth.
In the present study, we examined the bone changes in rhG-CSF-treated young and young adult rats in order to investigate the effect of age-related conditions of bone growth on the bone changes induced by rhG-CSE MATERIALS AND METHODS Animals. Thirty 4-wk-old and 30 12-wk-old male Sprague-Dawley rats were purchased from Japan SLC Inc. (Shizuoka) and acclimatized for 2 wk. They were subjected to the experiments at the ages of 6 and 14 wk. The animals were housed in taper-type suspended stainless-steel cages (5/cage) in an animal room maintained at a temperature of 23 ~-2°C and a humidity of 55 ± 10%, with 14-16 air changes per hour and a 14-hr light cycle, and they were fed pelleted chow (CE-2; Clea Japan Inc., Tokyo) and tap water ad libitum.
Recombinant Human G-CSF. Recombinant human G-CSF produced by Chugai Pharmaceutical Co. Ltd. (Tokyo) was used for this study (9, 16 Study Design. Groups of 10 rats received daily intra-venous injections of rhG-CSF in the tail vein at the dose levels of 100 or 1,000 ~g/kg for 28 days. The injection volume was adjusted to 4 ml/kg. In addition to these rhG-CSF-treated groups, an rhG-CSF-untreated control group was prepared. During the administration period, clinical signs of all animals were observed every day before the dosing and at 3 hr after the dosing. All animals were weighed on day 0 and once weekly thereafter until day 28. Peripheral blood leukocyte [white blood cell (WBC)] counts were measured in blood samples obtained from the dorsal metatarsal vein of each animal at day 27 (before dosing) using a multiparameter auto-cell counter (electrical resistance detection, CC-780; Toa Medical Electronic Co. Ltd., Hyogo, Japan). Bone Histopathology. On the day following the final administration, all animals were sacrificed by exsanguination under ether anesthesia. At necropsy, femurs (diaphysis to distal epiphysis), tibiae (diaphysis to distal epiphysis), calcanei, metatarsi, and digits were removed from all animals. The bones were fixed in 20% neutralbuffered formalin and embedded in paraffin after ethylenediaminetetraacetic acid decalcification. Longitudinal thin sections were made and stained with hematoxylin and eosin (H&E).
For the purpose of regional analysis, the femur, tibia, metatarsus, and digit were classified into 3 sites according to their histological structures, that is, epiphysis, metaphysis, and diaphysis. The calcaneus, which is irregular quadrangular bone, was not classified and was regarded as 1 site. In addition, the severity of bone lesions was scored according to the size of focus within each site (scores 0-4: 0 = no lesion, 1 = 1 small focus, 2 = 2-4 small foci, 3 = 5-9 small foci or corresponding middle foci, and 4 = more than 10 small foci or corresponding large foci). The scores from each site were totaled within each bone of each rat. The total score for a particular bone in each group was obtained. For each group, mean scores for a particular bone from affected rats were calculated as (total score for a particular bone by group) -(number of affected rats by group), and the mean scores for all bones were also totaled.
Analysis of Bone-Related Parameters. Serum samples from 6-wk-old rats were obtained from the abdominal aorta under ether anesthesia at day 28 and serum calcium was measured using the o-cresolphtalein complexon method. At necropsy, parathyroid and thyroid glands were removed from 6-wk-old rats and fixed in 20% neutral-buffered formalin, and H&E-stained sections were subjected to histopathologic evaluation.
RESULTS

Clinical Signs, Body Weights, and WBC Counts
No abnormal clinical signs were observed in any group. Figure 1 illustrates the body weights and body weight gains of the 6and 14-wk-old groups. The 6-wkold groups showed marked body weight gains. In contrast, the 14-wk-old groups showed slight body weight gains, and definite differences were observed between the 6and the 14-wk-old groups. A dose-dependent increase uaY&eth; Vi aUll11111&eth;lial.lVll FIG. 1.-Body weights and body weight gains of 6-(*, A, ·) and 14-(0, A, D) wk-old rats injected with 0 (control; ~, 0), 100 (A, A), and 1,000 (0, E) p-g/kg of rhG-CSE Each value represents the mean ± SD (n = 10).
in WBC counts was observed in rats of both age groups treated with rhG-CSF (Fig. 2 ). The increase in the 14-wkold groups was significantly higher than that in the dosematched 6-wk-old ones.
Histopathological Findings of = Bone Lesions
Bone lesions were observed in rats of both age groups; there was no age-related difference in the histopathological nature of the bone lesions. The lesions showed signs of both bone resorption and osteogenesis, and no hematopoietic cell areas were observed in the medullary cavity ( Fig. 3 ). In the spongy trabeculae and the endosteum region of compact bones with no hematopoietic cell areas, a large number of osteoclasts and bone resorption bays (Howship's lacunae) were observed on the bone surface (Fig. 4 ). The medullary cavity around or beside resorptive bones was replaced by mesenchymal tissues. In addition to the aforementioned findings, newly formed bones showing irregular shape, and woven bone structures that had no spicules of calcified cartilage were observed in and/or near the areas replaced by mesenchymal tissues. These bones were filled with osteoid osteocytes, -Peripheral blood leukocyte counts of rats injected with rhG-CSF for 27 days. Each value represents the mean ± SD (n = 10). **Significantly different between the 6-and 14-wk-old groups at the same dose levels (p < 0.01, Student's t-test).
and their surfaces were covered with mono-or multilayered formative osteoblasts (Fig. 5 ).
There was no age-related difference in the relationship between bone resorption and osteogenesis in the bone 
Incidence, Distribution, and Severity of Bone Lesions
Bone lesions were observed in 6-wk-old rats given 100 and 1,000 /-Lg/kg of rhG-CSF and in 14-wk-old rats given 1,000 /-Lg/kg of rhG-CSF In the groups treated with 1,000 Rg/kg of rhG-CSF, the number of rats with lesions was greater in the 6-wk-old group than in the 14-wk-old group (Table I ). In addition, the group mean number of bones affected and the group mean number of bones with lesions in an affected rat were both greater in the 6-wkold group than in the 14-wk-old group.
Lesions were mainly observed in the metaphysis in rats of both age groups (Table II ). In the 6-wk-old rats given 1,000 /-Lg/kg of rhG-CSF, the diaphysis and epiphysis were also sometimes involved. Metaphyseal and epiphyseal lesions were observed in the trabeculae of spongiosa, and diaphyseal lesions were observed in the endosteum region of compact bones. In the calcaneus, lesions were observed in the spongy bone near the growth plate in rats of both age groups. Table III . In all types of bones, the group mean scores for a particular H&E.
Scores for bone lesions are shown in
x 150. Abbreviations: F = femur; T = tibia; C = calcaneus; M = metatarsus; D = digits. a Bone lesion implies accelarated osteoclastic bone resroption on the existing bone and intramedullary osteogenesis due to intramembranous ossification.
b Each group is composed of 10 males. I Mean number of bones with lesions by group is calculated as (total number of bones with lesion for all bones by group) -7-(number of rats examined by group (n = 10)). d Mean number of bones with lesions in an affected rat by group is calculated as (total number of bones with lesion for all bones by group) (number of rats with bone lesions by group). bone in an affected rat were greater in the 6-wk-old groups than in the dose-matched 14-wk-old groups.
Changes in Bone-Related Parameters in
6-Wk-Old Rats
The mean of serum calcium levels and its standard deviation (n = 10) were 10.37 ±0.18 mg/dl for the control group, 10.35 ± 0.22 mg/dl for the 100-l-1g/kg group, and 10.37 ± 0.15 mg/dl for the 1,000-l-1g/kg group, respectively. In the parathyroid and thyroid glands, no abnormal pathological changes were observed in any group.
DISCUSSION
In this study, to elucidate the effect of age-related bone conditions in particular bone growth on bone lesions induced by a high dosage of rhG-CSF, rhG-CSF was given to rats by repeated intravenous injection for 28 days starting at the age of 6 or 14 wk. Bone lesions characterized by bone resorption as well as osteogenesis were observed in rhG-CSF-treated rats of both ages, and there was no age-related difference in the histopathological nature of the bone lesions. It was therefore suggested that the higher dose of rhG-CSF may intrinsically induce bone lesions with a particular histopathological nature in rats regardless of their age. However, clear differences were observed in the inci-TABLE III.-Scores for bone lesions, in rats injected with rhG-CSF for 28 days. a Bone lesion implies accelerated osteoclastic bone resorption on the existing bone and intramedullary osteogenesis due to intramembranous ossification. The severity of bone lesions was scored according to the size of lesions including bone resorption and osteogenesis. b Mean score for bone lesions in an affected rat by group is calculated as (total score for a particular bone by group) + (number of affected rats by group). dence, severity, and distribution of bone lesions between the 6-and 14-wk-old rats. Namely, the incidence of bone involvement and the severity of bone lesions were both greater in the 6-wk-old rats than in the dose-matched 14-wk-old rats. In addition, the bone lesions frequently occurred in the trabeculae of metaphyseal spongy bone and the endosteal of diaphyseal compact bone in the 6-wk-old rats, whereas the lesions were confined to the spongy bone trabeculae in the 14-wk-old rats. In contrast, the increase in WBC counts related to the major pharmacological activity of G-CSF (4, 7) was significantly higher in the 14-wk-old rats than in the dose-matched 6-wk-old ones. Therefore, the difference in the incidence, severity, and distribution of bone lesions between the 6and 14-wk-old rats is considered to be independent of the major pharmacological activity of G-CSE The fact that the 6-wk-old rats showed marked body weight gains while the 14-wk-old ones showed slight body weight gains may indicated that 6-wk-old rats are in growing stage whereas the 14-wk-old ones are in mature stage. It is well known that the activity of bone resorption and formation resulting from growth, modeling, and remodeling is higher in growing animals than in adults (1, 12) . This and the aforementioned findings strongly suggest that the development of bone lesions induced by rhG-CSF may be closely related to age-related conditions of bone growth and that the action of rhG-CSF on the bone may be stronger in young growing rats than in young adult ones.
In the 6-wk-old rats, which showed marked bone changes as compared to the 14-wk-old rats, there was no abnormal change in serum calcium levels and parathyroid/thyroid histopathology. The fact that bone changes induce by rhG-CSF were not associated with hypercalcemia and hyperparathyroidism suggests that rhG-CSF may have some local actions on the bone.
Histopathological analysis revealed that accelerated osteoclastic bone resorption was observed in almost all lesions, and osteogenesis was mostly observed accompanied by bone resorption. As previously reported (21) , it was suggested that osteoclastic bone resorption was accelerated and that osteogenesis due to intramembranous ossification following bone resorption occurred. Namely, bone resorption was accelerated in some way by rhG-CSF: and then this led to osteogenesis. The main action of rhG-CSF on bone, therefore, seems to be the acceleration of osteoclastic bone resorption. An acceleration of osteoclastic resorption involved 2 different processes: differentiation and formation of osteoclasts and their activation. At present, it is not clear which process rhG-CSF is most closely related to. However, it has been reported that G-CSF weakly stimulated growth of osteoclast progenitors in vitro (22) . On the other hand, there has been no evidence to indicate that G-CSF has some direct effects on mature osteoclasts. It is conceivable that rhG-CSF kept at high levels might result in strong stimulation on osteoclast progenitors. In addition, it has been shown that G-CSF affects not only hematopoietic cells but also stromal cells (3, 5) . These cells, which are components of marrow microenvironment, play an important role in modulating the development of osteoclasts (10, 17, 18, 20, 23) . It is possible that high levels of rhG-CSF may affect the marrow microenvironment and bring about osteoclast formation. Alternatively, G-CSF may have some actions on bone modulation through unknown mechanisms. Now, further study on the pathogenesis of rhG-CSF-induced bone changes is in progress.
